A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2  years and older

CONCLUSION: This clinical study showed good safety of the PPV23 vaccine candidate produced by Ab&b Biotechnology Co., Ltd.JS had good safety after vaccination in people aged 2 years and older. At the same time, good immunogenicity was also demonstrated.PMID:38519344 | DOI:10.1016/j.vaccine.2024.03.044

Source: Vaccine - March 22, 2024 Category: Allergy & Immunology Authors: Yuhui Zhang Yanxia Wang Guangfu Li Xue Zhao Kai Wang Chunyu Jia Yongli Yang Lili Huang Jiebing Tan Xiaofen Chen Wenna Leng Zhiqiang Xie Wei Zhang Juan Zong Kang Chen Qin Li Xiaocan Jia Dongyang Zhao Youcai An Yaodong Zhang Source Type: research